Pfizer (PFE:US) recently announced in "The Year Ahead, Biopharma Breakthroughs" that Gene Therapy is one of its hottest areas and that it is very active in three programs - DMD and two in haemophilia studies. PFE's market cap is ~ A$300 billion and they see DMD as one of their best areas for growth.
ANP is in the right place with room to grow - Pfizer is 10,000 times bigger.
Ann: Trial Met Primary & Exceeded Secondary Endpoint Expectations, page-208
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
